Statements (73)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:abacavir
gptkb:Abacavir |
| gptkbp:activities |
inhibits reverse transcriptase
|
| gptkbp:class |
gptkb:nucleoside_reverse_transcriptase_inhibitor
|
| gptkbp:clinical_trial |
Phase II
Phase III Phase I |
| gptkbp:contraindication |
severe hypersensitivity to abacavir
|
| gptkbp:dosage_form |
gptkb:tablet
oral solution |
| gptkbp:effective_date |
gptkb:1998
FDA approved |
| gptkbp:excretion |
urine
feces |
| gptkbp:financial_products |
D B00501
|
| gptkbp:form |
gptkb:tablet
oral solution |
| https://www.w3.org/2000/01/rdf-schema#label |
Ziagen
|
| gptkbp:indication |
HIV-1 infection
HIV-2 infection |
| gptkbp:ingredients |
gptkb:abacavir
|
| gptkbp:interacts_with |
gptkb:beer
other antiretroviral drugs |
| gptkbp:is_atype_of |
J05 A F01
|
| gptkbp:is_used_for |
treatment of HIV infection
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:marketed_as |
Abacavir sulfate
|
| gptkbp:monitors |
A0 D1 D1 B1 Z5
|
| gptkbp:packaging |
gptkb:beer
blister pack |
| gptkbp:pharmacokinetics |
metabolized in liver
bioavailability 83% half-life 1.5 hours |
| gptkbp:population |
gptkb:Person
adults |
| gptkbp:provides_information_on |
combination therapy
monotherapy |
| gptkbp:safety_features |
liver function tests
viral load C D4 count |
| gptkbp:side_effect |
gptkb:historical_event
gptkb:fandom gptkb:Insurance_Company anxiety dizziness fatigue headache muscle pain nausea weight loss abdominal pain fever sore throat vomiting diarrhea joint pain insomnia cardiovascular events lactic acidosis chills weight gain peripheral neuropathy skin rash thrombocytopenia hepatotoxicity pancreatitis neutropenia hypersensitivity reaction |
| gptkbp:social_structure |
C15 H18 N6 O5 S
|
| gptkbp:type_of |
136470-78-5
|